Direct access to verified contract research methodologies, molecular testing assays, and pilot validation services managed under rigorous GLP and ISO standards.
Global biopharmaceutical authorities (US FDA, EMA, NMPA) and dietary supplement compliance boards require defensible, reproducible, mechanistic efficacy documentation. Relying merely on historical consensus or anecdotal TCM claims no longer secures market clearance.
Complex natural extracts suffer batch deviations caused by geographical diversity and fluctuating harvest timings. Modern efficacy studies demand holistic metabolomic fingerprinting to lock target bioactives into precise physiological response corridors.
Entering the US, EU, and Asian markets demands robust mechanistic clearance. Preclinical dossiers require toxicity cross-referencing, in vitro cytotoxicity limits (IC50), and clear bio-marker tracking before initiating clinical testing protocols.
Dividing molecular characterization, animal pharmacokinetics, and commercial production between distinct suppliers degrades data integrity. True efficiency lies in an integrated CRO-CDMO continuum from extraction to human trials.
Combining immense botanical raw-material biodiversity with modern clinical pharmacology, Chinese research organizations yield accelerated research cycles and cost rationalization.
China hosts over 11,000 medicinal plant species across diverse bio-climatic zones. Our facilities directly evaluate geochemically distinct cultivars (Dao Di herbs) to isolate peak active potency, mitigating overseas shipping delays and multi-tier supply chain markups.
From microgram-level phenotypic cell screening to 10,000-liter multi-stage chromatography extraction, study protocols transfer smoothly into validated production runs, preserving your confidential know-how without third-party leaks.
Deep hospital networks, high cohort enrollment rates, and optimized laboratory infrastructure allow preclinical animal and human trials to conclude significantly faster than equivalent North American or European trial tracks.
Over 14+ years of data accumulation across high-throughput screening, multi-target validation, and collaborative registration filings.
Our study setups adapt specifically to the endpoint parameters required by nutraceutical regulatory submissions, botanical drug IND/NDAs, and dermatological efficacy standards.
Evaluation of anti-glycation properties, metabolic modulation, gut microbiome regulation, and adaptogenic benefits. We deliver small-cohort human intervention trials and cytokine-level bio-assays for rigorous structure-function label claims.
Indication-targeted multi-pathway validation for oncology adjuvants, neuroprotection, and metabolic disorders. Full preclinical IND dossiers covering pharmacokinetics (DMPK), target-affinity validation, and GLP safety evaluations.
Clinical skin brightening, anti-aging matrix metalloproteinase inhibition, dermal barrier repair, and sebum homeostasis assays. Supported by in vitro 3D human skin equivalents, patch tests, and clinical multi-spectral imaging.
Every program follows a transparent, phased engineering approach designed to de-risk investment and secure actionable clinical deliverables.
Mass spectrometry fingerprinting, target active screening, and evaluation of potency across harvest seasons and geographic origins to establish standardized baselines.
Evaluation of receptor binding affinities, cellular enzyme kinetics, radical scavenge capabilities, and cytotoxicity (IC50) across normal and challenged cell phenotypes.
Validated disease model testing (murine/porcine), systemic bioavailability studies, organ accumulation checks, and acute/subchronic toxicity profiles (LD50).
Double-blind placebo-controlled human efficacy studies, hospital preparation filings, or Phase I–IV clinical phases paired with commercial cGMP manufacturing.
Navigating jurisdictional differences between East and West requires rigorous protocol documentation, bilingual reporting, and strict intellectual property protection.
All trial datasets, statistical power calculations, and analytical methods (HPTLC, HPLC-MS/MS) are formatted for electronic Common Technical Document (eCTD) submissions, satisfying Western inspection frameworks.
Contractual research assignments ensure 100% of study data, custom chromatographic assays, extraction innovations, and clinical trial results remain our client's exclusive intellectual assets under strict mutual NDA frameworks.
Direct project steering with PhD toxicologists and trial coordinators fluent in English and Chinese, ensuring transparent bi-weekly milestone updates, rapid change-order response, and seamless timezone management.
Our efficacy pipelines and quality standards have advanced product pipelines for tier-one pharmaceutical corporations and top-level medical universities across China.
Tongrentang Group
CR Sanjiu Medical
Sunflower Pharma
Livzon Pharma Group
Dihon Pharma Group
Golden Throat Group
Yangtzi River Pharma
Beihai Gofar Biological
Humanwell Healthcare
SCIMYTH Pharma
Shandong Hanfang
Luoxin Pharma Stock
Zhongsheng Pharma
Brilliance & Abundance
Apeloa Pharmaceutical
Heng Chang Pharma
Baotou TCM Co.
Kamp Medicine
Guangxi Santo Pharma
Hunan Kangshou
Jiangxi Juwang Pharma
Beijing Tcmages
Guizhou Ruihe Pharma
Anhui CR Jinchan
Kangmei Pharmaceutical
Hunan Tianjicaotang
Kingstone Unite Pharma
Shuguang Hospital (SH)
Hunan Affiliated TCM
First Hospital Hunan TCM
Second Xiangya Hospital
Second Hospital Hunan TCM
TCM Zhuzhou Hospital
In-depth answers addressing experimental models, protocol transfers, compliance documentation, and scale-up manufacturing.
Select a specific research track to initiate pilot studies, request analytical specifications, or scale full-batch commercial production.
Connect directly with our senior pharmacology committee to evaluate your molecule or extract target, review regulatory feasibility, and receive an itemized study proposal.
